DETERMINATION OF IN VITRO CYTOTOXICITY OF ENTRECTINIB AND PEMIGATINIB NANOSPONGES TABLETS ON A 498, MCF-7 AND PANC-1 CELL LINES

PALANATI MAMATHA; BHIKSHAPATHI D. V. R. N.

doi:10.22159/ijpps.2024v16i2.49567

Authors

PALANATI MAMATHA Teegala Ram Reddy College of Pharmacy, Pragathi Colony, Meerpet, Hyderabad–500097, Telangana, India
BHIKSHAPATHI D. V. R. N. Teegala Ram Reddy College of Pharmacy, Pragathi Colony, Meerpet, Hyderabad–500097, Telangana, India

DOI:

https://doi.org/10.22159/ijpps.2024v16i2.49567

Keywords:

Pemigatinib, Entrectinib, Biliary tract cancer, Nanosponges, Cytotoxicity, Cell lines

Abstract

Objective: The aim of this study was to improve the oral solubility of Pemigatinib and Entrectinib through incorporation into nanosponges (NSs), and further the cytotoxic potential of optimized formulations of NSs on A498, MCF-7, and PANC-1 cell lines in the MTT based Cell proliferation assay was analyzed.

Methods: In the current study Pemigatinib and Entrectinib were formulated in to NS tablets and cytotoxicity was determined by using A498, MCF-7, and PANC-1 cell lines. The optimized NS formulation was determined prepared into a tablet dosage form, which further was evaluated for physical parameters and in vitro drug release study. For cytotoxicity studies, MTT assay was conducted for these formulations, IC₅₀ values were calculated for the tested compound and compared with 5-Fluorouracil.

Results: The optimized formulation was evaluated for physical parameters and in vitro drug release study, the results were satisfactory. The IC50 of Entrectinib NS, Pemigatinib NS and 5-Fluorouracil, against A498 cell line was 26.34, 85.24 and 15.24 µg/ml, respectively. The IC50 of Entrectinib NS, Pemigatinib NS and 5-Fluorouracil, against MCF-7 cell line was 71.54, 35.48 and 24.56 µg/ml, respectively. The IC50 of Entrectinib NS, Pemigatinib NS and 5-Fluorouracil, against PANC-1 cell line was 35.14, 22.54 and 22.54 µg/ml, respectively. It was observed that the IC₅₀ of drug-loaded NS was higher than the comparator drug and these enter the cells by active transport and induce cytotoxicity to the cells.

Conclusion: The overall results from the studies suggest that Entrectinib NS and Pemigatinib NS provided efficient cytotoxic effects, which could play a significant role in the percentage cell death.

Downloads

Download data is not yet available.

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209-49. doi: 10.3322/caac.21660, PMID 33538338.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Jun;68(6):394-424. doi: 10.3322/caac.21492, PMID 30207593.

Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019 Jan;51(1):27-41. doi: 10.1016/j.immuni.2019.06.025, PMID 31315034.

Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B. Combination therapy in combating cancer. Oncotarget. 2017 Jun;8(23):38022-43. doi: 10.18632/oncotarget.16723, PMID 28410237.

Wen H, Jung H, Li X. Drug delivery approaches in addressing clinical pharmacology-related issues: opportunities and challenges. AAPS J. 2015 Jun;17(6):1327-40. doi: 10.1208/s12248-015-9814-9, PMID 26276218.

Hassan S, Peluso J, Chalhoub S, Idoux Gillet Y, Benkirane Jessel N, Rochel N. Quercetin potentializes the respective cytotoxic activity of gemcitabine or doxorubicin on 3D culture of AsPC-1 or HepG2 cells, through the inhibition of HIF-1α and MDR1. Plos One. 2020 Oct;15(10):e0240676. doi: 10.1371/journal.pone.0240676, PMID 33052979.

Novero A, Ravella PM, Chen Y, Dous G, Liu D. Ibrutinib for B cell malignancies. Exp Hematol Oncol Oncol 2014. 2014;3(1):4. doi: 10.1186/2162-3619-3-4, PMID 24472371.

Pal Singh S, Dammeijer F, Hendriks RW. Role of bruton's tyrosine kinase in B cells and malignancies. Mol Cancer. 2018 Jan;17(1):57. doi: 10.1186/s12943-018-0779-z, PMID 29455639.

Xia S, Liu X, Cao X, Xu S. T-cell expression of bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia. Cell Mol Immunol. 2020 Oct;17(10):1042-52. doi: 10.1038/s41423-019-0270-9, PMID 31431692.

Salehi B, Machin L, Monzote L, Sharifi Rad J, Ezzat SM, Salem MA. Therapeutic potential of quercetin: new insights and perspectives for human health. ACS Omega. 2020 May;5(20):11849-72. doi: 10.1021/acsomega.0c01818, PMID 32478277.

Ye Q, Liu K, Shen Q, Li Q, Hao J, Han F. Reversal of multidrug resistance in cancer by multi-functional flavonoids. Front Oncol. 2019 Jun;9:487. doi: 10.3389/fonc.2019.00487, PMID 31245292.

Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. E Cancer Medical Science. 2019;13:961.

Gupta M. Inorganic nanoparticles: an alternative therapy to combat drug-resistant infections. Int J Pharm Pharm Sci. 2021 Aug;13(8):20-31. doi: 10.22159/ijpps.2021v13i8.42643.

Sarvan, Vashisth H. Types and application of pharmaceutical nanotechnology: a review. Int J Curr Pharm Sci 2023;15(3):14-8. doi: 10.22159/ijcpr.2023v15i3.3010.

Ankem B, Kucharlapati SLT, Magapu SD, BB. Nanosponges–a revolutionary targeted drug delivery nanocarrier: a review. Asian J Pharm Clin Res. 2023 Apr;16(4):3-9. doi: 10.22159/ajpcr.2023.v16i4.46453.

Subair TK, Mohanan J. Development of nano-based film forming gel for prolonged dermal delivery of luliconazole. Int J Pharm Pharm Sci. 2022 Feb;14(2):31-41. doi: 10.22159/ijpps.2022v14i2.43253.

Sharma P, Sharma A, Gupta A. Nanosponges: as a dynamic drug delivery approach for targeted delivery. Int J App Pharm. 2023 May;15(3):1-11. doi: 10.22159/ijap.2023v15i3.46976.

Aldawsari MF, Alhowail AH, Anwer MK, Ahmed MM. Development of diphenyl carbonate-crosslinked cyclodextrin based nanosponges for oral delivery of baricitinib: formulation, characterization and pharmacokinetic studies. Int J Nanomedicine. 2023 Apr;18:2239-51. doi: 10.2147/IJN.S405534, PMID 37139486.

Anwer MK, Ahmed MM, Aldawsari MF, Iqbal M, Kumar V. Preparation and evaluation of diosmin-loaded diphenylcarbonate-cross-linked cyclodextrin nanosponges for breast cancer therapy. Pharmaceuticals (Basel). 2022 Dec;16(1):19. doi: 10.3390/ph16010019, PMID 36678517.

Patel M, Sawant K. A quality by design concept on lipid-based nanoformulation containing antipsychotic drug: screening design and optimization using response surface methodology. J Nanomed Nanotechnol. 2017 May;08(3):1-11. doi: 10.4172/2157-7439.1000442.

Rezaei A, Varshosaz J, Fesharaki M, Farhang A, Jafari SM. Improving the solubility and in vitro cytotoxicity (anticancer activity) of ferulic acid by loading it into cyclodextrin nanosponges. Int J Nanomedicine. 2019 Jun;14:4589-99. doi: 10.2147/IJN.S206350, PMID 31296988.

Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res. 2002 Apr;62(4):1139-47. PMID 11861395.

Chen WH, Lu G, Chen X, Zhao XM, Bork P. OGEE v2: an update of the online gene essentiality database with special focus on differentially essential genes in human cancer cell lines. Nucleic Acids Res. 2017 Jan;45(D1):D940-4. doi: 10.1093/nar/gkw1013, PMID 27799467.

Mohsin K, Long MA, Pouton CW. Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution. J Pharm Sci. 2009 Oct;98(10):3582-95. doi: 10.1002/jps.21659, PMID 19130605.

Cerpnjak K, Zvonar A, Gasperlin M, Vrecer F. Lipid-based systems as a promising approach for enhancing the bioavailability of poorly water-soluble drugs. Acta Pharm. 2013 Apr;63(4):427-45. doi: 10.2478/acph-2013-0040, PMID 24451070.

Sharma K, Kadian V, Kumar A, Mahant S, Rao R. Evaluation of solubility, photostability and antioxidant activity of ellagic acid cyclodextrin nanosponges fabricated by melt method and microwave-assisted synthesis. J Food Sci Technol. 2022 Mar;59(3):898-908. doi: 10.1007/s13197-021-05085-6, PMID 35153320.

Wu XW, Wang RF, Yuan M, Xu W, Yang XW. Dulbecco’s modified Eagle’s medium and minimum essential medium-which one is more preferred for establishment of caco-2 cell monolayer model used in evaluation of drug absorption? Pharmazie. 2013 Oct;68(10):805-10. PMID 24273884.

Bahraminasab M, Arab S, Jahan A. Adaptation of MC3T3 cell line to dulbecco’s modified Eagle’s medium. Tissue Cell. 2020 Sep;64:101341. doi: 10.1016/j.tice.2020.101341, PMID 32473711.

Scott J, Dorr RT, Samulitis B, Landowski TH. Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines. Cancer Chemother Pharmacol. 2007 Jun;59(6):749-57. doi: 10.1007/s00280-006-0329-z, PMID 17333195.

Rubinstein LV, Shoemaker RH, Paull KD, Simon RM, Tosini S, Skehan P. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst. 1990;82(13):1113-8. doi: 10.1093/jnci/82.13.1113, PMID 2359137.

Ramadan MA, Shawkey AE, Rabeh MA, Abdellatif AO. Expression of P53, BAX, and BCL-2 in human malignant melanoma and squamous cell carcinoma cells after tea tree oil treatment in vitro. Cytotechnology. 2019 Jan;71(1):461-73. doi: 10.1007/s10616-018-0287-4, PMID 30599074.

Yu WX, Lu C, Wang B, Ren XY, Xu K. Effects of rapamycin on osteosarcoma cell proliferation and apoptosis by inducing autophagy. Eur Rev Med Pharmacol Sci. 2020 Feb;24(2):915-21. doi: 10.26355/eurrev_202001_20076, PMID 32016998.